OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)

CAPS Rating: 3 out of 5

Caps

How do you think OMED will perform against the market?

Add Stock to CAPS Watchlist

All Players

28 Outperform
3 Underperform
 

All-Star Players

6 Outperform
1 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top OMED Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Tophinater (35.92)
Submitted November 17, 2014

i don't know.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

OMED VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about OMED.

Recs

0
Member Avatar DeathStock (95.85) Submitted: 4/10/2017 4:23:29 PM : Outperform Start Price: $5.51 OMED Score: -14.78

Not really a fan of this company or stock but I'll take a chance with a 200M market cap in place now as it was overpriced from the IPO.

Recs

0
Member Avatar adamicius (< 20) Submitted: 3/17/2017 11:07:01 AM : Outperform Start Price: $10.17 OMED Score: -57.42

Another hopeful junior Celgene partner working on drugs targeting cancer stem cell pathways and immuno-oncology treatments.

Recs

0
Member Avatar biotechf (27.72) Submitted: 7/17/2015 1:54:24 PM : Outperform Start Price: $21.43 OMED Score: -97.30

Oncomed's two most promising cancer treatments are demcizumab and tarextumab targeting difficult to treat cancers. Positive clinical trial results should give these shares a boost. Both of these drugs have partnerships: demcizumab (Celgene) and tarextumab (GSK). At $21.50 per share or about 654M market capitalization the company may increase in value if phase trial results are positive.

OncoMed is conducting two randomized Phase 2 trials of demcizumab. The YOSEMITE trial is evaluating demcizumab and gemcitabine plus Abraxane in patients with first-line metastatic pancreatic cancers. The DENALI trial will assess the efficacy of demcizumab with carboplatin and pemetrexed in first-line non-squamous NSCLC. A Phase 1b/2 trial of demcizumab and paclitaxel in patients with platinum-resistant ovarian cancer is also ongoing.

Tarextumab (anti-Notch2/3, OMP-59R5) is a novel anti-cancer stem cell antibody that prevents signaling through both the Notch2 and Notch3 receptors. Tarextumab is currently being studied in two randomized Phase 2 clinical trials. The ALPINE trial is assessing tarextumab with Abraxane plus gemcitabine in first-line advanced pancreatic cancer patients. The PINNACLE trial is testing tarextumab in combination with etoposide and cisplatin and etoposide and carboplatin in first-line extensive stage small cell lung cancer patients.

Leaderboard

Find the members with the highest scoring picks in OMED.

Score Leader

TrackJimCramer

TrackJimCramer (85.15) Score: +107.58

The Score Leader is the player with the highest score across all their picks in OMED.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
oscillation 78.64 1/25/2016 Underperform 5Y $10.05 -48.13% +36.35% +84.48 0 Comment
wadea1 < 20 1/28/2016 Underperform 5Y $8.94 -41.72% +36.05% +77.77 0 Comment
PoolSkunk 69.11 8/1/2017 Outperform 5Y $2.97 +75.18% +4.28% +70.90 0 Comment
portefeuille2 99.34 8/29/2017 Outperform 5Y $4.59 +13.51% +5.42% +8.09 0 Comment
portefeuille 98.77 4/11/2017 Outperform 5Y $5.11 +2.06% +9.99% -7.93 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. DeathStock 95.85 4/10/2017 Outperform 5Y $5.51 -5.44% +9.34% -14.78 1 Comment
adamicius < 20 3/17/2017 Outperform 5Y $10.17 -48.77% +8.65% -57.42 1 Comment
mistermiranga 99.65 7/7/2016 Outperform 5Y $12.69 -58.94% +23.25% -82.20 0 Comment
biotechf 27.72 7/17/2015 Outperform 1Y $21.43 -75.69% +21.61% -97.30 1 Comment
sullyz0r 55.14 5/28/2015 Outperform 5Y $23.83 -78.14% +21.47% -99.61 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
trackmizuho < 20 2/11/2014 Outperform NS $33.62 -84.50% +43.13% -127.63 0 Comment
TrackJimCramer 85.15 11/7/2013 Underperform 3W $13.08 -60.17% +47.41% +107.58 0 Comment

Featured Broker Partners